9th March 2021
Mucormycosis emerging as new worry in COVID-19 world.
Biospectrum India, 9th March 2021:
Bharat Serums & Vaccines (BSV) is the first company in India to get a DCGI approval for anti-fungal medication Liposomal Amphotericin B, used for treating deadly mucormycosis. BSV is also marketing Liposomal Amphotericin B in India and exporting it to many other countries. Lipid complex Amphotericin B has also been recommended by international clinical guidelines for the management of IFIs including pulmonary aspergillosis. Lipid Emulsion Amphotericin B is recommended for the treatment of Visceral leishmaniasis.
About BSV
BSV has been a pioneer in the development of blood components and therapeutic antibody products for infectious and non-infectious diseases. For over four decades, BSVL has focused on utilizing its scientific resources to develop several biological, biotechnology and pharmaceutical products to treat various types of diseases, contributing to preserve, protect and enhance the quality of life. We aim to be a leading biopharmaceutical company driven by people & science to set benchmarks in patient outcomes in Women’s Health, Critical Care & Emergency Medicine.
For more information, please contact:
Irawati Gowariker, BSV, Irawati.gowariker@bsvgroup.com